Landiolol in Postoperative Atrial Fibrillation (MMELPOAF)
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
Postoperative atrial fibrillation is a common complication after cardiac surgery and is associated with an elevation of morbidity and mortality. The recommended treatment includes heart rate control with a beta blocker. Landiolol is a new-generation beta-blocker with favourable pharmacologic properties making an interesting drug to treat postoperative atrial fibrillation. However, Landiolol micro and macrocirculatory effects in the setting of atrial fibrillation are yet to describe. The aim of this study is to describe microcirculatory effects of incremental doses of landiolol in postoperative atrial fibrillation compared to a placebo. Our hypothesis is Landiolol will improve microcirculation disorders.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Patient underwent conventional cardiac surgery
- Age > 18 years
- Writing contentment
Exclusion criteria
- Pre-existing chronic atrial fibrillation
- Contraindication to beta-blockers
- Circulatory shock (cardiac index<2.2 L/min and lactate>4mmol/L)
- Distributive shock (cardiac index>2.2 L/min with norepinephrine dose > 0.3 µg/kg/min to reach mean arterial pressure > 65mmHg).
- Acute respiratory distress
- Major bleeding (>200mL/h)
- Patient already included into an interventional clinical study
- Pregnancy
- No social security insurance
- Patient not able to give consent (curators, patients deprived of public rights)
Trial design
Primary purpose
Allocation
Interventional model
Masking
58 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal